Having found that colon cancer–associated TOP1 up-regulation is correlated with lower DoG RNAs levels, we hypothesized that the therapeutic benefits of inhibiting TOP1 activity with CPT may be linked to increased DoG RNA levels in colon cancer. Here, TOP1 is linked to colonic neoplasm.